为肝细胞癌武装 GPC3 CAR T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
98.9分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
mRNA 电转 HBV-TCR T 细胞治疗 HBV-HCC
英文原题：HBV-HCC treatment with mRNA electroporated HBV-TCR T cells.
研究概要
肝细胞癌是一项重大的全球健康挑战，其在东亚地区的发病率持续上升。
中文摘要
肝细胞癌是全球重要的健康挑战，在东亚地区发病率持续上升。丙型和乙型肝炎病毒感染导致多数HCC病例；针对HCV的强效抗病毒药物问世后，病因构成逐渐偏向慢性HBV感染，而目前尚无有效治愈方法。因此，HBV相关HCC仍是持续存在的全球性问题。中晚期HBV相关HCC的治疗选择有限，亟需新的治疗策略。鉴于过继T细胞免疫疗法治疗B细胞恶性肿瘤已取得显著成功，有理由探索其是否同样可用于HBV相关HCC。本综述介绍HBV相关HCC的T细胞治疗策略发展，并讨论这些策略的安全性及疗效，包括直接杀伤肿瘤细胞以及T细胞可能诱发的其他改变。
展开英文摘要原文
Hepatocellular carcinoma is a significant global health challenge with steadily increasing incidence in the East Asia region. While both Hepatitis C and B virus infections account for the majority of HCC cases, the advent of potent antivirals against HCV infection has biased the aetiology towards chronic HBV infection that at the moment remains without an effective cure. For this reason, HBV-HCC remains a persistent global problem. Treatment options for intermediate to advanced stages of HBV-HCC remain limited, hence novel therapeutic strategies are required to fulfil this medical need. Following the considerable success of adoptive T-cell immunotherapy against B-cell malignancies, it is conceivable to envision whether the same could be achieved against HBV-HCC. In this review, we describe the development of T-cell therapy strategies for HBV-HCC and discuss the safety and the efficacy of the strategies in terms of the direct killing of tumour cells and the other alterations possibly induced by the action of the T cells.
论文信息
- 作者
- Tan AT、Bertoletti A
- 单位
- Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.Singapore
- 文献类型
- 综述
- 期刊
- Immunotherapy advances2022
- 原文标识
- PubMed 35919490 · DOI 10.1093/immadv/ltab026